logo.png
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
18 juil. 2024 09h00 HE | BIOXYTRAN, INC.
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
logo.png
Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
27 juin 2024 13h09 HE | BIOXYTRAN, INC.
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
logo.png
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
06 mars 2024 09h00 HE | BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
logo.png
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
21 févr. 2024 08h00 HE | BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
logo.png
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
24 oct. 2023 08h45 HE | BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
logo.png
Bioxytran Interview at the Emerging Growth Conference
04 oct. 2023 09h00 HE | BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
logo.png
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
14 sept. 2023 09h41 HE | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
logo.png
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
24 août 2023 09h00 HE | BIOXYTRAN, INC.
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
logo.png
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
08 août 2023 07h00 HE | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
logo.png
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
31 juil. 2023 07h00 HE | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...